Oral delivery of macromolecular drugs: Where we are after almost 100 years of attempts

Advanced Drug Delivery Reviews

Volumn 101, Issue , 2016, Pages 108-121

  Moroz, Elena ^a   Matoori, Simon ^a   Leroux, Jean Christophe ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Biologics; High molecular weight; Oral bioavailability; Oral drug delivery; Permeation enhancers; Protease inhibitors

Indexed keywords

BIOCHEMISTRY; DRUG PRODUCTS;

BIOLOGICS; HIGH MOLECULAR WEIGHT; ORAL BIOAVAILABILITIES; ORAL DRUG DELIVERY; PERMEATION ENHANCERS; PROTEASE INHIBITOR;

MACROMOLECULES;

ADALIMUMAB; ALICAFORSEN; ANTISENSE OLIGONUCLEOTIDE; AXITINIB; BACTERIAL TOXIN; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CYTOKINE; DOLCANATIDE; EXCIPIENT; FIDAXOMICIN; HYDROXYPROPYLMETHYLCELLULOSE; INFLIXIMAB; LFF 571; LINACLOTIDE; MESSENGER RNA; MONGERSEN; OLIGONUCLEOTIDE; PANCRELIPASE; PEPTIDE; PLECANATIDE; POLYCLONAL ANTIBODY; PROTEINASE INHIBITOR; RUCAPARIB; SMAD7 PROTEIN; SUROTOMYCIN; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VANCOMYCIN; VIRULENCE FACTOR; DRUG; INSULIN;

CELL PROTECTION; CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MARKETING; ENZYME REPLACEMENT; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE MUCOSA PERMEABILITY; IRRITABLE COLON; MACROMOLECULE; PHARMACEUTICS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; ULCERATIVE COLITIS; ADMINISTRATION AND DOSAGE; ANIMAL; BIOAVAILABILITY; INTESTINE ABSORPTION; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; RISK ASSESSMENT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; EXCIPIENTS; HUMANS; INSULIN; INTESTINAL ABSORPTION; MACROMOLECULAR SUBSTANCES; PEPTIDES; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT;

EID: 84957922509     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.01.010     Document Type: Review

References (145)

1. [1] Joslin, E., Gray, H., Root, H.F., Insulin in hospital and home. J. Metab. Res. 2 (1922), 651–699.
2. [2] Choonara, B.F., Choonara, Y.E., Kumar, P., Bijukumar, D., du Toit, L.C., Pillay, V., A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules. Biotechnol. Adv. 32 (2014), 1269–1282.
3. [3] Hwang, S.R., Byun, Y., Advances in oral macromolecular drug delivery. Expert Opin. Drug Deliv. 11 (2014), 1955–1967.
4. [4] Fuhrmann, G., Leroux, J.-C., Improving the stability and activity of oral therapeutic enzymes-recent advances and perspectives. Pharm. Res. 31 (2014), 1099–1105.
5. [5] Goldberg, M., Gomez-Orellana, I., Challenges for the oral delivery of macromolecules. Nat. Rev. Drug Discov. 2 (2003), 289–295.
6. [6] Ménard, S., Cerf-Bensussan, N., Heyman, M., Multiple facets of intestinal permeability and epithelial handling of dietary antigens. Mucosal Immunol. 3 (2010), 247–259.
7. [7] Rieux, A. des, Pourcelle, V., Cani, P.D., Marchand-Brynaert, J., Préat, V., Targeted nanoparticles with novel non-peptidic ligands for oral delivery. Adv. Drug Deliv. Rev. 65 (2013), 833–844.
8. [8] Jepson, M.A., Clark, M.A., Hirst, B.H., M cell targeting by lectins: a strategy for mucosal vaccination and drug delivery. Adv. Drug Deliv. Rev. 56 (2004), 511–525.
9. [9] Jepson, M.A., Clark, M.A., Studying M cells and their role in infection. Trends Microbiol. 6 (1998), 359–365.
10. [10] Maher, S., Brayden, D.J., Overcoming poor permeability: translating permeation enhancers for oral peptide delivery. Drug Discov. Today Technol. 9 (2012), e71–e174.
11. [11] Tillman, L.G., Geary, R.S., Hardee, G.E., Oral delivery of antisense oligonucleotides in man. J. Pharm. Sci. 97 (2008), 225–236.
12. [12] Doak, B.C., Over, B., Giordanetto, F., Kihlberg, J., Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. Chem. Biol. 21 (2014), 1115–1142.
13. [13] Wang, S., Liu, H., Zhang, X., Qian, F., Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. Protein Cell 6 (2015), 480–503.
14. [14] O'Ryan, M., Vidal, R., del Canto, F., Salazar, J.C., Montero, D., Vaccines for viral and bacterial pathogens causing acute gastroenteritis: part I: overview, vaccines for enteric viruses and Vibrio cholerae. Hum. Vaccin. Immunother. 11 (2015), 584–600.
15. [15] O'Ryan, M., Vidal, R., del Canto, F., Carlos Salazar, J., Montero, D., Vaccines for viral and bacterial pathogens causing acute gastroenteritis: part II: vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni. Hum. Vaccin. Immunother. 11 (2015), 601–619.
16. [16] Lycke, N., Recent progress in mucosal vaccine development: potential and limitations. Nat. Rev. Immunol. 12 (2012), 592–605.
17. [17] Jones, R.G.A., Martino, A., Targeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications. Crit. Rev. Biotechnol., 2015.
18. [18] Mangsbo, S.M., Sanchez, J., Anger, K., Lambris, J.D., Ekdahl, K.N., Loskog, A.S., Nilsson, B., Tötterman, T.H., Complement activation by CpG in a human whole blood loop system: mechanisms and immunomodulatory effects. J. Immunol. 183 (2009), 6724–6732.
19. [19] Pawar, V.K., Meher, J.G., Singh, Y., Chaurasia, M., Surendar Reddy, B., Chourasia, M.K., Targeting of gastrointestinal tract for amended delivery of protein/peptide therapeutics: strategies and industrial perspectives. J. Control. Release 196 (2014), 168–183.
20. [20] Levine, D.P., Vancomycin: a history. Clin. Infect. Dis. 42:Suppl. 1 (2006), S5–12.
21. [21] van Wageningen, A.A.M., Kirkpatrick, P.N., Williams, D.H., Harris, B.R., Kershaw, J.K., Lennard, N.J., Jones, M., Jones, S.J., Solenberg, P.J., Sequencing and analysis of genes involved in the biosynthesis of a vancomycin group antibiotic. Chem. Biol. 5 (1998), 155–162.
22. [22] Jordan, D.C., Inniss, W.E., Selective inhibition of ribonucleic acid synthesis in Staphylococcus aureus by vancomycin. Nature 184 (1959), 1894–1895.
23. [23] Lemaitre, F., Hasni, N., Leprince, P., Corvol, E., Belhabib, G., Fillâtre, P., Luyt, C.E., Leven, C., Farinotti, R., Fernandez, C., Combes, A., Propofol, midazolam, vancomycin and cyclosporine therapeutic drug monitoring in extracorporeal membrane oxygenation circuits primed with whole human blood. Crit. Care., 19, 2015.
24. [24] Rao, S., Kupfer, Y., Pagala, M., Chapnick, E., Tessler, S., Systemic absorption of oral vancomycin in patients with Clostridium difficile infection. Scand. J. Infect. dis. 43 (2011), 386–388.
25. [25] Mullane, K., Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance. Ther. Adv. Chronic Dis. 5 (2014), 69–84.
26. [26] Jarrad, A.M., Karoli, T., Blaskovich, M.A.T., Lyras, D., Cooper, M.A., Clostridium difficile drug pipeline: challenges in discovery and development of new agents. J. Med. Chem. 58 (2015), 5164–5185.
27. [27] Ivarsson, M.E., Leroux, J.-C., Castagner, B., Investigational new treatments for clostridium difficile infection. Drug Discov. Today 20 (2015), 602–608.
28. [28] Bryant, A.P., Busby, R.W., Bartolini, W.P., Cordero, E.A., Hannig, G., Kessler, M.M., Pierce, C.M., Solinga, R.M., Tobin, J.V., Mahajan-Miklos, S., Cohen, M.B., Kurtz, C.B., Currie, M.G., Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci. 86 (2010), 760–765.
29. [29] Busby, R.W., Bryant, A.P., Bartolini, W.P., Cordero, E. a, Hannig, G., Kessler, M.M., Mahajan-Miklos, S., Pierce, C.M., Solinga, R.M., Sun, L.J., Tobin, J.V., Kurtz, C.B., Currie, M.G., Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur. J. Pharmacol. 649 (2010), 328–335.
30. [30] Castro, J., Harrington, A.M., Hughes, P. a, Martin, C.M., Ge, P., Shea, C.M., Jin, H., Jacobson, S., Hannig, G., Mann, E., Cohen, M.B., MacDougall, J.E., Lavins, B.J., Kurtz, C.B., Silos-Santiago, I., Johnston, J.M., Currie, M.G., Blackshaw, L.A., Brierley, S.M., Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3′,5′-monophosphate. Gastroenterology 145 (2013), 1334–1346 (e1–11).
31. [31] Layer, P., Stanghellini, V., Review article: linaclotide for the management of irritable bowel syndrome with constipation. Aliment. Pharm. Ther. 39 (2014), 371–384.
32. [32] Busby, R.W., Kessler, M.M., Bartolini, W.P., Bryant, A.P., Hannig, G., Higgins, C.S., Solinga, R.M., Tobin, J.V., Wakefield, J.D., Kurtz, C.B., Currie, M.G., Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J. Pharmacol. Exp. Ther. 344 (2013), 196–206.
33. [33] Liu, D., Overbey, D., Watkinson, L.D., Daibes-Figueroa, S., Hoffman, T.J., Forte, L.R., Volkert, W.A., Giblin, M.F., In vivo imaging of human colorectal cancer using radiolabeled analogs of the uroguanylin peptide hormone. Anticancer Res. 29 (2009), 3777–3783.
34. [34] Miner, P.B., Surowitz, R., Fogel, R., Koltun, W., Drossman, D.A., Camilleri, M., Mangel, A., Barrow, L., Jacob, G.S., Shailubhai, K., 925g Plecanatide, a novel guanylate cyclase-C (GC-C) receptor agonist, is efficacious and safe in patients with chronic idiopathic constipation (CIC): results from a 951 patient, 12 week, multi-center trial. Gastroenterology, 144, 2013 (S–163.).
35. [35] Shailubhai, K., Foss, J., Zhang, G., Arjunan, K., Feng, R., Comiskey, S., Jacob, G., Plevy, S., SP-333, a guanylate cyclase C agonist, ameliorates DSS-colitis in mice via a novel cyclic GMP-mediated mechanism: P-198. Inflamm. Bowel Dis. 18 (2012), S93–S94.
36. [36] Chaparro, M., Guerra, I., Muñoz-Linares, P., Gisbert, J.P., Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease. Aliment. Pharm. Ther. 35 (2012), 971–986.
37. [37] Lakatos, P., Miheller, P., Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD?. Curr. Drug Targets 11 (2010), 179–186.
38. [38] Ford, A.C., Peyrin-Biroulet, L., Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am. J. Gastroenterol. 108 (2013), 1268–1276.
39. [39] Bhol, K.C., Tracey, D.E., Lemos, B.R., Lyng, G.D., Erlich, E.C., Keane, D.M., Quesenberry, M.S., Holdorf, A.D., Schlehuber, L.D., Clark, S.A., Fox, B.S., AVX-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease. Inflamm. Bowel Dis. 19 (2013), 2273–2281.
40. [40] Hurley, W.L., Theil, P.K., Perspectives on immunoglobulins in colostrum and milk. Nutrients 3 (2011), 442–474.
41. [41] Kelly, C.P., Chetham, S., Keates, S., Bostwick, E.F., Roush, A.M., Castagliuolo, I., LaMont, J.T., Pothoulakis, C., Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Antimicrob. Agents Chemother. 41 (1997), 236–241.
42. [42] Warny, M., Fatimi, A., Bostwick, E.F., Laine, D.C., Lebel, F., LaMont, J.T., Pothoulakis, C., Bovine immunoglobulin concentrate-clostridium difficile retains C. difficile toxin neutralising activity after passage through the human stomach and small intestine. Gut 44 (1999), 212–217.
43. [43] Vandenbroucke, K., de Haard, H., Beirnaert, E., Dreier, T., Lauwereys, M., Huyck, L., Van Huysse, J., Demetter, P., Steidler, L., Remaut, E., Cuvelier, C., Rottiers, P., Orally administered L. lactis secreting an anti-TNF nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol. 3 (2010), 49–56.
44. [44] Fraissl, L., Leitner, R., Missbichler, A., Novel formulation of neutral lactase improves digestion of dairy products in case of lactose intolerance. Clin. Transl. Allergy., 1, 2011, P104.
45. [45] Montalto, M., Curigliano, V., Santoro, L., Vastola, M., Cammarota, G., Manna, R., Gasbarrini, A., Gasbarrini, G., Management and treatment of lactose malabsorption. World J. Gastroenterol. 12 (2006), 187–191.
46. [46] Matoori, S., Fuhrmann, G., Leroux, J.C., Celiac disease: a challenging disease for pharmaceutical scientists. Pharm. Res. 30 (2013), 619–626.
47. [47] Fuhrmann, G., Grotzky, A., Lukić, R., Matoori, S., Luciani, P., Yu, H., Zhang, B., Walde, P., Schlüter, A.D., Gauthier, M.A., Leroux, J.C., Sustained gastrointestinal activity of dendronized polymer-enzyme conjugates. Nat. Chem. 5 (2013), 582–589.
48. [48] Hoskins, J.A., Jack, G., Wade, H.E., Peiris, R.J., Wright, E.C., Starr, D.J., Stern, J., Enzymatic control of phenylalanine intake in phenylketonuria. Lancet 1 (1980), 392–394.
49. [49] Gass, J., Ehren, J., Strohmeier, G., Isaacs, I., Khosla, C., Fermentation, purification, formulation, and pharmacological evaluation of a prolyl endopeptidase from Myxococcus xanthus: implications for celiac sprue therapy. Biotechnol. Bioeng. 92 (2005), 674–684.
50. [50] Schulz, J.D., Patt, M., Basler, S., Kries, H., Hilvert, D., Gauthier, M.A., Leroux, J.-C., Site-specific polymer conjugation stabilizes therapeutic enzymes in the gastrointestinal tract. Adv. Mater., 2015, 10.1002/adma.201504797.
51. [51] Limaye, S.A., Haddad, R.I., Cilli, F., Sonis, S.T., Colevas, A.D., Brennan, M.T., Hu, K.S., Murphy, B.A., Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer 119 (2013), 4268–4276.
52. [52] Caluwaerts, S., Vandenbroucke, K., Steidler, L., Neirynck, S., Vanhoenacker, P., Corveleyn, S., Watkins, B., Sonis, S., Coulie, B., Rottiers, P., AG013, a mouth rinse formulation of Lactococcus lactis secreting human trefoil factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis. Oral Oncol. 46 (2010), 564–570.
53. [53] Vermeire, S., Rutgeerts, P.J., D'Haens, G.R., De Vos, M., Bressler, B., Van der Aa, A., Coulie, B., Wong, C.J., Feagan, B.G., 46 A phase 2a randomized placebo-controlled double-blind multi-center dose escalation study to evaluate the safety, tolerability, pharmacodynamics and efficacy of AG011 in patients with moderately active ulcerative colitis. Gastroenterology, 138, 2010 (S–9.).
54. [54] Galipeau, H.J., Wiepjes, M., Motta, J.-P., Schulz, J.D., Jury, J., Natividad, J.M., Pinto-Sanchez, I., Sinclair, D., Rousset, P., Martin-Rosique, R., Bermudez-Humaran, L., Leroux, J.C., Murray, J.A., Smecuol, E., Bai, J.C., Vergnolle, N., Langella, P., Verdu, E.F., Novel role of the serine protease inhibitor elafin in gluten-related disorders. Am. J. Gastroenterol. 109 (2014), 748–756.
55. [55] Lee, S.H., Castagner, B., Leroux, J.C., Is there a future for cell-penetrating peptides in oligonucleotide delivery?. Eur. J. Pharm. Biopharm. 85 (2013), 5–11.
56. [56] Kriegel, C., Attarwala, H., Amiji, M., Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tract. Adv. Drug Deliv. Rev. 65 (2013), 891–901.
57. [57] O'Neill, M.J., Bourre, L., Melgar, S., O'Driscoll, C.M., Intestinal delivery of non-viral gene therapeutics: physiological barriers and preclinical models. Drug Discov. Today 16 (2011), 203–218.
58. [58] An, R., Jia, Y., Wan, B., Zhang, Y., Dong, P., Li, J., Liang, X., Non-enzymatic depurination of nucleic acids: factors and mechanisms. PLoS ONE, 9, 2014, e115950.
59. [59] Putney, S.D., Benkovic, S.J., Schimmel, P.R., A DNA fragment with an alpha-phosphorothioate nucleotide at one end is asymmetrically blocked from digestion by exonuclease III and can be replicated in vivo. Proc. Natl. Acad. Sci. U. S. A. 78 (1981), 7350–7354.
60. [60] Deleavey, G.F., Damha, M.J., Designing chemically modified oligonucleotides for targeted gene silencing. Chem. Biol. 19 (2012), 937–954.
61. [61] Monteleone, G., Neurath, M.F., Ardizzone, S., Di Sabatino, A., Fantini, M.C., Castiglione, F., Scribano, M.L., Armuzzi, A., Caprioli, F., Sturniolo, G.C., Rogai, F., Vecchi, M., Atreya, R., Bossa, F., Onali, S., Fichera, M., Corazza, G.R., Biancone, L., Savarino, V., Pica, R., Orlando, A., Pallone, F., Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N. Engl. J. Med. 372 (2015), 1104–1113.
62. [62] Monteleone, G., Fantini, M.C., Onali, S., Zorzi, F., Sancesario, G., Bernardini, S., Calabrese, E., Viti, F., Monteleone, I., Biancone, L., Pallone, F., Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Mol. Ther. 20 (2012), 870–876.
63. [63] Vegter, S., Tolley, K., Wilson Waterworth, T., Jones, H., Jones, S., Jewell, D., Meta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis. Aliment. Pharm. Ther. 38 (2013), 284–293.
64. [64] Miner, P., Wedel, M., Bane, B., Bradley, J., An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment. Pharm. Ther. 19 (2004), 281–286.
65. [65] Inomata, M., Ochiai, A., Akimoto, S., Kitano, S., Hirohashi, S., Alteration of beta-catenin expression in colonic epithelial cells of familial adenomatous polyposis patients. Cancer Res. 56 (1996), 2213–2217.
66. [66] Vaze, M.B., Wu, T., Seth, S., Templin, M., Polisky, B., Engineering of trans kingdom RNAi (tkRNAi) against gastrointestinal polyps. Cancer Res., 72, 2014, 5706.
67. [67] Lee, S.H., Moroz, E., Castagner, B., Leroux, J.-C., Activatable cell penetrating peptide–peptide nucleic acid conjugate via reduction of azobenzene PEG chains. J. Am. Chem. Soc. 136 (2014), 12868–12871.
68. [68] Wang, J., Yadav, V., Smart, A.L., Tajiri, S., Basit, A.W., Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs. Mol. Pharm. 12 (2015), 966–973.
69. [69] Pohl, E., Heine, A., Sheldrick, G.M., Dauter, Z., Wilson, K.S., Kallen, J., Huber, W., Pfäffli, P.J., Structure of octreotide, a somatostatin analogue. Acta Crystallogr. D. 51 (1995), 48–59.
70. [70] Thanou, M., Verhoef, J.C., Marbach, P., Junginger, H.E., Intestinal absorption of octreotide: N-trimethyl chitosan chloride (TMC) ameliorates the permeability and absorption properties of the somatostatin analogue in vitro and in vivo. J. Pharm. Sci. 89 (2000), 951–957.
71. [71] Köhler, E., Duberow-Drewe, M., Drewe, J., Ribes, G., Loubatiéres-Mariani, M.M., Mazer, N., Gyr, K., Beglinger, C., Absorption of an aqueous solution of a new synthetic somatostatin analogue administered to man by gavage. Eur. J. Clin. Pharmacol. 33 (1987), 167–171.
72. [72] Tuvia, S., Pelled, D., Marom, K., Salama, P., Levin-Arama, M., Karmeli, I., Idelson, G.H., Landau, I., Mamluk, R., A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms. Pharm. Res. 31 (2014), 2010–2021.
73. [73] Tuvia, S., Atsmon, J., Teichman, S.L., Katz, S., Salama, P., Pelled, D., Landau, I., Karmeli, I., Bidlingmaier, M., Strasburger, C.J., Kleinberg, D.L., Melmed, S., Mamluk, R., Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J. Clin. Endocrinol. Metab. 97 (2012), 2362–2369.
74. [74] Melmed, S., Popovic, V., Bidlingmaier, M., Mercado, M., van der Lely, A.J., Biermasz, N., Bolanowski, M., Coculescu, M., Schopohl, J., Racz, K., Glaser, B., Goth, M., Greenman, Y., Trainer, P., Mezosi, E., Shimon, I., Giustina, A., Korbonits, M., Bronstein, M.D., Kleinberg, D., Teichman, S., Gliko-Kabir, I., Mamluk, R., Haviv, A., Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J. Clin. Endocrinol. Metab. 100 (2015), 1699–1708.
75. [75] Robinson, A.G., DDAVP in the treatment of central diabetes insipidus. N. Engl. J. Med. 294 (1976), 507–511.
76. [76] Lundin, S., Artursson, P., Absorption of a vasopressin analogue, 1-deamino-8-d-arginine-vasopressin (dDAVP), in a human intestinal epithelial cell line, CaCO-2. Int. J. Pharm. 64 (1990), 181–186.
77. [77] Fjellestad-Paulsen, A., Höglund, P., Lundin, S., Paulsen, O., Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. Clin. Endocrinol. 38 (1993), 177–182.
78. [78] Osterberg, O., Savic, R.M., Karlsson, M.O., Simonsson, U.S.H., Nørgaard, J.P., Walle, J.V., Agersø, H., Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults. J. Clin. Pharmacol. 46 (2006), 1204–1211.
79. [79] Rittig, S., Jensen, A.R., Jensen, K.T., Pedersen, E.B., Effect of food intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (DDAVP) in hydrated normal subjects. Clin. Endocrinol. 48 (1998), 235–241.
80. [80] Robson, W.L.M., Leung, A.K.C., Norgaard, J.P., The comparative safety of oral versus intranasal desmopressin for the treatment of children with nocturnal enuresis. J. Urol. 178 (2007), 24–30.
81. [81] Fricker, G., Drewe, J., Huwyler, J., Gutmann, H., Beglinger, C., Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br. J. Pharmacol. 118 (1996), 1841–1847.
82. [82] Beck, J.G., Chatterjee, J., Laufer, B., Kiran, M.U., Frank, A.O., Neubauer, S., Ovadia, O., Greenberg, S., Gilon, C., Hoffman, A., Kessler, H., Intestinal permeability of cyclic peptides: common key backbone motifs identified. J. Am. Chem. Soc. 134 (2012), 12125–12133.
83. [83] Choc, M.G., Bioavailability and pharmacokinetics of cyclosporine formulations: neoral vs sandimmune. Int. J. Dermatol. 36:Suppl. 1 (1997), 1–6.
84. [84] Kovarik, J.M., Mueller, E.A., Van Bree, J.B., Tetzloff, W., Kutz, K., Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J. Pharm. Sci. 83 (1994), 444–446.
85. [85] Mueller, E.A., Kovarik, J.M., van Bree, J.B., Grevel, J., Lücker, P.W., Kutz, K., Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm. Res. 11 (1994), 151–155.
86. [86] Rivier, J.E., Jiang, G., Porter, J., Hoeger, C.A., Craig, A.G., Corrigan, A., Vale, W., Rivier, C.L., Gonadotropin-releasing hormone antagonists: novel members of the azaline B family. J. Med. Chem. 38 (1995), 2649–2662.
87. [87] Leonard, T.W., Lynch, J., McKenna, M.J., Brayden, D.J., Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET. Expert Opin. Drug Del. 3 (2006), 685–692.
88. [88] Amory, J.K., Leonard, T.W., Page, S.T., O'Toole, E., McKenna, M.J., Bremner, W.J., Oral administration of the GnRH antagonist acyline, in a GIPET-enhanced tablet form, acutely suppresses serum testosterone in normal men: single-dose pharmacokinetics and pharmacodynamics. Cancer Chemother. Pharmacol. 64 (2009), 641–645.
89. [89] Chesnut, C.H., Azria, M., Silverman, S., Engelhardt, M., Olson, M., Mindeholm, L., Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos. Int. 19 (2008), 479–491.
90. [90] Petersen, S.B., Nielsen, L.G., Rahbek, U.L., Guldbrandt, M., Brayden, D.J., Colonic absorption of salmon calcitonin using tetradecyl maltoside (TDM) as a permeation enhancer. Eur. J. Pharm. Sci. 48 (2013), 726–734.
91. [91] Karsdal, M.A., Byrjalsen, I., Riis, B.J., Christiansen, C., Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon Calcitonin. BMC Clin. Pharmacol., 8, 2008.
92. [92] Karsdal, M.A., Byrjalsen, I., Henriksen, K., Riis, B.J., Lau, E.M., Arnold, M., Christiansen, C., The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study. Osteoarthr. Cartil. 18 (2010), 150–159.
93. [93] Binkley, N., Bolognese, M., Sidorowicz-Bialynicka, A., Vally, T., Trout, R., Miller, C., Buben, C.E., Gilligan, J.P., Krause, D.S., A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. J. Bone Miner. Res. 27 (2012), 1821–1829.
94. [94] Welling, S.H., Hubálek, F., Jacobsen, J., Brayden, D.J., Rahbek, U.L., Buckley, S.T., The role of citric acid in oral peptide and protein formulations: relationship between calcium chelation and proteolysis inhibition. Eur. J. Pharm. Biopharm. 86 (2014), 544–551.
95. [95] Binkley, N., Bone, H., Gilligan, J.P., Krause, D.S., Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial. Osteoporos. Int. 25 (2014), 2649–2656.
96. [96] Lempicki, K.A., Borchert, J.S., Cancer risk associated with calcitonin use. J. Am. Geriatr. Soc. 62 (2014), 2447–2450.
97. [97] Lorenz, M., Evers, A., Wagner, M., Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity. Bioorg. Med. Chem. Lett. 23 (2013), 4011–4018.
98. [98] Heinemann, L., Jacques, Y., Oral insulin and buccal insulin: a critical reappraisal. J. Diabetes Sci. Technol. 3 (2009), 568–584.
99. [99] Zijlstra, E., Heinemann, L., Plum-Mörschel, L., Oral insulin reloaded: a structured approach. J. Diabetes Sci. Technol. 8 (2014), 458–465.
100. [100] Fonte, P., Araújo, F., Reis, S., Sarmento, B., Oral insulin delivery: how far are we?. J. Diabetes Sci. Technol. 7 (2013), 520–531.
101. [101] Maher, S., Ryan, B., Duffy, A., Brayden, D.J., Formulation strategies to improve oral peptide delivery. Pharm. Pat. Anal. 3 (2014), 313–336.
102. [102] Luzio, S.D., Dunseath, G., Lockett, A., Broke-Smith, T.P., New, R.R., Owens, D.R., The glucose lowering effect of an oral insulin (capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes. Diabetes Obes. Metab. 12 (2010), 82–87.
103. [103] Eldor, R., Kidron, M., Arbit, E., Open-label study to assess the safety and pharmacodynamics of five oral insulin formulations in healthy subjects. Diabetes Obes. Metab. 12 (2010), 219–223.
104. [104] Eldor, R., Arbit, E., Corcos, A., Kidron, M., Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study. PLoS ONE, 8, 2013, e59524.
105. [105] Kidron, M., Dinh, S., Menachem, Y., Abbas, R., Variano, B., Goldberg, M., Arbit, E., Bar-On, H., A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects. Diabet. Med. 21 (2004), 354–357.
106. [106] Hazra, P., Adhikary, L., Dave, N., Khedkar, A., Manjunath, H.S., Anantharaman, R., Iyer, H., Development of a process to manufacture PEGylated orally bioavailable insulin. Biotechnol. Prog. 26 (2010), 1695–1704.
107. [107] Hazra, P., Chatterjee, A., Shabandri, Q., Adhikary, L., Dave, N., Buddha, M., A novel one-pot de-blocking and conjugation reaction step leads to process intensification in the manufacture of PEGylated insulin IN-105. Bioprocess Biosyst. Eng. 35 (2012), 1333–1341.
108. [108] Khedkar, A., Iyer, H., Anand, A., Verma, M., Krishnamurthy, S., Savale, S., Atignal, A., A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects. Diabetes Obes. Metab. 12 (2010), 659–664.
109. [109] Geho, W.B., Geho, H.C., Lau, J.R., Gana, T.J., Hepatic-directed vesicle insulin: a review of formulation development and preclinical evaluation. J. Diabetes Sci. Technol. 3 (2009), 1451–1459.
110. [110] Geho, W.B., Rosenberg, L.N., Schwartz, S.L., Lau, J.R., Gana, T.J., A single-blind, placebo-controlled, dose-ranging trial of oral hepatic-directed vesicle insulin add-on to oral antidiabetic treatment in patients with type 2 diabetes mellitus. J. Diabetes Sci. Technol. 8 (2014), 551–559.
111. [111] Bernstein, G., Delivery of insulin to the buccal mucosa utilizing the RapidMist system. Expert Opin. Drug Del. 5 (2008), 1047–1055.
112. [112] Palermo, A., Napoli, N., Manfrini, S., Lauria, A., Strollo, R., Pozzilli, P., Buccal spray insulin in subjects with impaired glucose tolerance: the prevoral study. Diabetes Obes. Metab. 13 (2011), 42–46.
113. [113] Khatsenko, O., Morgan, R., Truong, L., York-Defalco, C., Sasmor, H., Conklin, B., Geary, R.S., Absorption of antisense oligonucleotides in rat intestine: effect of chemistry and length. Antisense Nucleic Acid Drug Dev. 10 (2000), 35–44.
114. [114] Dirin, M., Winkler, J., Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides. Expert. Opin. Biol. Ther. 13 (2013), 875–888.
115. [115] Raoof, A.A., Chiu, P., Ramtoola, Z., Cumming, I.K., Teng, C., Weinbach, S.P., Hardee, G.E., Levin, A.A., Geary, R.S., Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate. J. Pharm. Sci. 93 (2004), 1431–1439.
116. [116] Brenner, T., Hamra-Amitay, Y., Evron, T., Boneva, N., Seidman, S., Soreq, H., The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis. FASEB J. 17 (2003), 214–222.
117. [117] Sussman, J.D., Argov, Z., McKee, D., Hazum, E., Brawer, S., Soreq, H., Antisense treatment for myasthenia gravis: experience with monarsen. Ann. N. Y. Acad. Sci. 1132 (2008), 283–290.
118. [118] Angelini, C., Martignago, S., Bisciglia, M., New treatments for myasthenia: a focus on antisense oligonucleotides. Drug Des. Devel. Ther. 7 (2013), 13–17.
119. [119] Sussman, J., Argov, Z., Wirguin, Y., Apolski, S., Milic-Rasic, V., Soreq, H., Further developments with antisense treatment for myasthenia gravis. Ann. N. Y. Acad. Sci. 1275 (2012), 13–16.
120. [120] Bernkop-Schnürch, A., The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J. Control. Release 52 (1998), 1–16.
121. [121] Watanabe, S., Takeuchi, T., Chey, W.Y., Mediation of trypsin inhibitor-induced pancreatic hypersecretion by secretin and cholecystokinin in rats. Gastroenterology 102 (1992), 621–628.
122. [122] Otsuki, M., Ohki, A., Okabayashi, Y., Suehiro, I., Baba, S., Effect of synthetic protease inhibitor camostate on pancreatic exocrine function in rats. Pancreas 2 (1987), 164–169.
123. [123] Melmed, R.N., El-Aaser, A.A., Holt, S.J., Hypertrophy and hyperplasia of the neonatal rat exocrine pancreas induced by orally administered soybean trypsin inhibitor. Biochim. Biophys. Acta 421 (1976), 280–288.
124. [124] Ge, Y.C., Morgan, R.G., The effect of trypsin inhibitor on the pancreas and small intestine of mice. Br. J. Nutr. 70 (1993), 333–345.
125. [125] Hastewell, J., The colonic absorption of human calcitonin: the effects of increasing local concentration and co-administration with a protease inhibitor. Int. J. Pharm. 126 (1995), 245–251.
126. [126] Yamamoto, A., Taniguchi, T., Rikyuu, K., Tsuji, T., Fujita, T., Murakami, M., Muranishi, S., Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm. Res. 11 (1994), 1496–1500.
127. [127] Drapeau, G., Petitclerc, E., Toulouse, A., Marceau, F., Dissociation of the antimicrobial activity of bacitracin USP from its renovascular effects. Antimicrob. Agents Chemother. 36 (1992), 955–961.
128. [128] Gibo, J., Ito, T., Kawabe, K., Hisano, T., Inoue, M., Fujimori, N., Oono, T., Arita, Y., Nawata, H., Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity. Lab. Investig. 85 (2005), 75–89.
129. [129] Coote, K., Atherton-Watson, H.C., Sugar, R., Young, A., MacKenzie-Beevor, A., Gosling, M., Bhalay, G., Bloomfield, G., Dunstan, A., Bridges, R.J., Sabater, J.R., Abraham, W.M., Tully, D., Pacoma, R., Schumacher, A., Harris, J., Danahay, H., Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease. J. Pharmacol. Exp. Ther. 329 (2009), 764–774.
130. [130] Aungst, B.J., Absorption enhancers: applications and advances. AAPS J. 14 (2012), 10–18.
131. [131] Maher, S., Leonard, T.W., Jacobsen, J., Brayden, D.J., Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic. Adv. Drug Deliv. Rev. 61 (2009), 1427–1449.
132. [132] Krug, S.M., Amasheh, M., Dittmann, I., Christoffel, I., Fromm, M., Amasheh, S., Sodium caprate as an enhancer of macromolecule permeation across tricellular tight junctions of intestinal cells. Biomaterials 34 (2013), 275–282.
133. [133] Quan, Y.S., Hattori, K., Lundborg, E., Fujita, T., Murakami, M., Muranishi, S., Yamamoto, A., Effectiveness and toxicity screening of various absorption enhancers using Caco-2 cell monolayers. Biol. Pharm. Bull. 21 (1998), 615–620.
134. [134] Raoof, A.A., Ramtoola, Z., McKenna, B., Yu, R.Z., Hardee, G., Geary, R.S., Effect of sodium caprate on the intestinal absorption of two modified antisense oligonucleotides in pigs. Eur. J. Pharm. Sci. 17 (2002), 131–138.
135. [135] Chao, A.C., Nguyen, J.V., Broughall, M., Griffin, A., Fix, J.A., Daddona, P.E., In vitro and in vivo evaluation of effects of sodium caprate on enteral peptide absorption and on mucosal morphology. Int. J. Pharm. 191 (1999), 15–24.
136. [136] Lindmark, T., Söderholm, J.D., Olaison, G., Alván, G., Ocklind, G., Artursson, P., Mechanism of absorption enhancement in humans after rectal administration of ampicillin in suppositories containing sodium caprate. Pharm. Res. 14 (1997), 930–935.
137. [137] Alani, A.W.G., Robinson, J.R., Mechanistic understanding of oral drug absorption enhancement of cromolyn sodium by an amino acid derivative. Pharm. Res. 25 (2008), 48–54.
138. [138] Riley, M.G.I., Castelli, M.C., Paehler, E.A., Subchronic oral toxicity of salcaprozate sodium (SNAC) in Sprague–Dawley and Wistar rats. Int. J. Toxicol. 28 (2009), 278–293.
139. [139] Hess, S., Rotshild, V., Hoffman, A., Investigation of the enhancing mechanism of sodium N-[8-(2-hydroxybenzoyl)amino]caprylate effect on the intestinal permeability of polar molecules utilizing a voltage clamp method. Eur. J. Pharm. Sci. 25 (2005), 307–312.
140. [140] Bittner, B., McIntyre, C., Tian, H., Tang, K., Shah, N., Phuapradit, W., Ahmed, H., Chokshi, H., Infeld, M., Fotaki, N., Ma, H., Portron, A., Jordan, P., Schmidt, J., Phase I clinical study to select a novel oral formulation for ibandronate containing the excipient sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC). Pharmazie 67 (2012), 233–241.
141. [141] Castelli, M.C., Wong, D.F., Friedman, K., Riley, M.G.I., Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC): an open-label, randomized, single-dose, parallel-group study in healthy male subjects. Clin. Ther. 33 (2011), 934–945.
142. [142] Steinert, R.E., Poller, B., Castelli, M.C., Drewe, J., Beglinger, C., Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects. Am. J. Clin. Nutr. 92 (2010), 810–817.
143. [143] Lerner, A., Matthias, T., Changes in intestinal tight junction permeability associated with industrial food additives explain the rising incidence of autoimmune disease. Autoimmun. Rev. 14 (2015), 479–489.
144. [144] Chassaing, B., Koren, O., Goodrich, J.K., Poole, A.C., Srinivasan, S., Ley, R.E., Gewirtz, A.T., Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 519 (2015), 92–96.
145. [145] Mrázek, J., Koppová, I., Kopecný, J., Simůnek, J., Fliegerová, K., PCR-DGGE-based study of fecal microbial stability during the long-term chitosan supplementation of humans. Folia Microbiol. 55 (2010), 352–358.